Effect of previous chloroquine intake on in vivo P. falciparum drug sensitivity

R. A. Bayoumi, F. K. Dar, M. O M Tanira, R. S. Stephen, M. M. Hussein, N. E. Hammo, R. I. Omer, M. F. Beidas, A. Shalabi, M. El-Wasila

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Investigation of the in vivo response of P. falciparum malaria parasites to chloroquine was conducted during 1993/94 in Al-Ain District of Abu Dhabi Emirate, UAE. Sixty seven expatriates who developed falciparum malaria on their return from Pakistan, Oman and Sudan were recruited for the WHO in vivo tests. Of the 67 patients, eight were classified as having RII and RIII responses, while 59 remained aparasitaemic at the end of the seven-day WHO standard test. On continuation into the 28-day WHO extended test, a further 34 patients exhibited RI resistance. Resistance of parasites to chloroquine was confirmed by measurement of plasma chloroquine using High-Performance Liquid Chromatography. In all 67 patients, the level of chloroquine was well above the minimum therapeutic level. The outcome of the in vivo test in patients treated for the first time was significantly different from that in patients who were previously on chloroquine. Among patients treated for the first time, 36 out of 41 (88%) had a resistant response, whereas, among those previously on chloroquine only six out of 26 (23%) had a resistant response. The difference is probably due to the higher initial plasma level of chloroquine among patients who were previously on the drug. Curing more patients with higher plasma chloroquine implies that chloroquine shall continue to be useful, particularly if resistance is at the RI level. Appropriate higher therapeutic levels of chloroquine should be defined for such patients.

Original languageEnglish
Pages (from-to)278-282
Number of pages5
JournalEast African Medical Journal
Volume74
Issue number5
Publication statusPublished - 1997

Fingerprint

Chloroquine
Pharmaceutical Preparations
Falciparum Malaria
Plasmas
Parasites
United Arab Emirates
Oman
Sudan
Pakistan
High performance liquid chromatography
Curing
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bayoumi, R. A., Dar, F. K., Tanira, M. O. M., Stephen, R. S., Hussein, M. M., Hammo, N. E., ... El-Wasila, M. (1997). Effect of previous chloroquine intake on in vivo P. falciparum drug sensitivity. East African Medical Journal, 74(5), 278-282.

Effect of previous chloroquine intake on in vivo P. falciparum drug sensitivity. / Bayoumi, R. A.; Dar, F. K.; Tanira, M. O M; Stephen, R. S.; Hussein, M. M.; Hammo, N. E.; Omer, R. I.; Beidas, M. F.; Shalabi, A.; El-Wasila, M.

In: East African Medical Journal, Vol. 74, No. 5, 1997, p. 278-282.

Research output: Contribution to journalArticle

Bayoumi, RA, Dar, FK, Tanira, MOM, Stephen, RS, Hussein, MM, Hammo, NE, Omer, RI, Beidas, MF, Shalabi, A & El-Wasila, M 1997, 'Effect of previous chloroquine intake on in vivo P. falciparum drug sensitivity', East African Medical Journal, vol. 74, no. 5, pp. 278-282.
Bayoumi RA, Dar FK, Tanira MOM, Stephen RS, Hussein MM, Hammo NE et al. Effect of previous chloroquine intake on in vivo P. falciparum drug sensitivity. East African Medical Journal. 1997;74(5):278-282.
Bayoumi, R. A. ; Dar, F. K. ; Tanira, M. O M ; Stephen, R. S. ; Hussein, M. M. ; Hammo, N. E. ; Omer, R. I. ; Beidas, M. F. ; Shalabi, A. ; El-Wasila, M. / Effect of previous chloroquine intake on in vivo P. falciparum drug sensitivity. In: East African Medical Journal. 1997 ; Vol. 74, No. 5. pp. 278-282.
@article{87d918919d104be5b9980327043973f2,
title = "Effect of previous chloroquine intake on in vivo P. falciparum drug sensitivity",
abstract = "Investigation of the in vivo response of P. falciparum malaria parasites to chloroquine was conducted during 1993/94 in Al-Ain District of Abu Dhabi Emirate, UAE. Sixty seven expatriates who developed falciparum malaria on their return from Pakistan, Oman and Sudan were recruited for the WHO in vivo tests. Of the 67 patients, eight were classified as having RII and RIII responses, while 59 remained aparasitaemic at the end of the seven-day WHO standard test. On continuation into the 28-day WHO extended test, a further 34 patients exhibited RI resistance. Resistance of parasites to chloroquine was confirmed by measurement of plasma chloroquine using High-Performance Liquid Chromatography. In all 67 patients, the level of chloroquine was well above the minimum therapeutic level. The outcome of the in vivo test in patients treated for the first time was significantly different from that in patients who were previously on chloroquine. Among patients treated for the first time, 36 out of 41 (88{\%}) had a resistant response, whereas, among those previously on chloroquine only six out of 26 (23{\%}) had a resistant response. The difference is probably due to the higher initial plasma level of chloroquine among patients who were previously on the drug. Curing more patients with higher plasma chloroquine implies that chloroquine shall continue to be useful, particularly if resistance is at the RI level. Appropriate higher therapeutic levels of chloroquine should be defined for such patients.",
author = "Bayoumi, {R. A.} and Dar, {F. K.} and Tanira, {M. O M} and Stephen, {R. S.} and Hussein, {M. M.} and Hammo, {N. E.} and Omer, {R. I.} and Beidas, {M. F.} and A. Shalabi and M. El-Wasila",
year = "1997",
language = "English",
volume = "74",
pages = "278--282",
journal = "East African Medical Journal",
issn = "0012-835X",
publisher = "East African Medical Association",
number = "5",

}

TY - JOUR

T1 - Effect of previous chloroquine intake on in vivo P. falciparum drug sensitivity

AU - Bayoumi, R. A.

AU - Dar, F. K.

AU - Tanira, M. O M

AU - Stephen, R. S.

AU - Hussein, M. M.

AU - Hammo, N. E.

AU - Omer, R. I.

AU - Beidas, M. F.

AU - Shalabi, A.

AU - El-Wasila, M.

PY - 1997

Y1 - 1997

N2 - Investigation of the in vivo response of P. falciparum malaria parasites to chloroquine was conducted during 1993/94 in Al-Ain District of Abu Dhabi Emirate, UAE. Sixty seven expatriates who developed falciparum malaria on their return from Pakistan, Oman and Sudan were recruited for the WHO in vivo tests. Of the 67 patients, eight were classified as having RII and RIII responses, while 59 remained aparasitaemic at the end of the seven-day WHO standard test. On continuation into the 28-day WHO extended test, a further 34 patients exhibited RI resistance. Resistance of parasites to chloroquine was confirmed by measurement of plasma chloroquine using High-Performance Liquid Chromatography. In all 67 patients, the level of chloroquine was well above the minimum therapeutic level. The outcome of the in vivo test in patients treated for the first time was significantly different from that in patients who were previously on chloroquine. Among patients treated for the first time, 36 out of 41 (88%) had a resistant response, whereas, among those previously on chloroquine only six out of 26 (23%) had a resistant response. The difference is probably due to the higher initial plasma level of chloroquine among patients who were previously on the drug. Curing more patients with higher plasma chloroquine implies that chloroquine shall continue to be useful, particularly if resistance is at the RI level. Appropriate higher therapeutic levels of chloroquine should be defined for such patients.

AB - Investigation of the in vivo response of P. falciparum malaria parasites to chloroquine was conducted during 1993/94 in Al-Ain District of Abu Dhabi Emirate, UAE. Sixty seven expatriates who developed falciparum malaria on their return from Pakistan, Oman and Sudan were recruited for the WHO in vivo tests. Of the 67 patients, eight were classified as having RII and RIII responses, while 59 remained aparasitaemic at the end of the seven-day WHO standard test. On continuation into the 28-day WHO extended test, a further 34 patients exhibited RI resistance. Resistance of parasites to chloroquine was confirmed by measurement of plasma chloroquine using High-Performance Liquid Chromatography. In all 67 patients, the level of chloroquine was well above the minimum therapeutic level. The outcome of the in vivo test in patients treated for the first time was significantly different from that in patients who were previously on chloroquine. Among patients treated for the first time, 36 out of 41 (88%) had a resistant response, whereas, among those previously on chloroquine only six out of 26 (23%) had a resistant response. The difference is probably due to the higher initial plasma level of chloroquine among patients who were previously on the drug. Curing more patients with higher plasma chloroquine implies that chloroquine shall continue to be useful, particularly if resistance is at the RI level. Appropriate higher therapeutic levels of chloroquine should be defined for such patients.

UR - http://www.scopus.com/inward/record.url?scp=0031435954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031435954&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 278

EP - 282

JO - East African Medical Journal

JF - East African Medical Journal

SN - 0012-835X

IS - 5

ER -